Sana Biotechnology (NASDAQ:SANA) Hits New 52-Week Low – Time to Sell?

Sana Biotechnology, Inc. (NASDAQ:SANA – Get Free Report) shares reached a new 52-week low during mid-day trading on Thursday. The stock traded as low as $1.82 and last traded at $1.8150, with a volume of 185,345 shares. The stock had previously closed at $1.85.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Citigroup lowered their target price on Sana Biotechnology to $11.00 and set a “buy” rating for the company in a report on Monday. Wall Street Zen upgraded shares of Sana Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. Bank of America reduced their price target on shares of Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Weiss Ratings cut shares of Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, November 11th. Finally, TD Cowen raised shares of Sana Biotechnology to a “strong-buy” rating in a research note on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.83.

Get Our Latest Report on Sana Biotechnology

Sana Biotechnology Stock Performance

The company has a 50 day moving average of $2.62 and a 200 day moving average of $3.24. The stock has a market capitalization of $537.84 million, a price-to-earnings ratio of -3.37 and a beta of 2.30.

Sana Biotechnology (NASDAQ:SANA – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. As a group, research analysts expect that Sana Biotechnology, Inc. will post -0.51 EPS for the current fiscal year.

Institutional Trading of Sana Biotechnology

Large investors have recently made changes to their positions in the company. Allworth Financial LP raised its holdings in Sana Biotechnology by 880.8% in the third quarter. Allworth Financial LP now owns 13,123 shares of the company’s stock valued at $38,000 after acquiring an additional 11,785 shares in the last quarter. Aquatic Capital Management LLC purchased a new position in Sana Biotechnology in the third quarter worth approximately $548,000. Goldman Sachs Group Inc. grew its holdings in Sana Biotechnology by 13.2% during the 3rd quarter. Goldman Sachs Group Inc. now owns 2,680,550 shares of the company’s stock worth $7,814,000 after acquiring an additional 312,615 shares in the last quarter. Toronto Dominion Bank grew its holdings in Sana Biotechnology by 0.3% during the 3rd quarter. Toronto Dominion Bank now owns 1,978,964 shares of the company’s stock worth $5,769,000 after acquiring an additional 6,583 shares in the last quarter. Finally, Palumbo Wealth Management LLC increased its position in shares of Sana Biotechnology by 39.6% in the 3rd quarter. Palumbo Wealth Management LLC now owns 83,462 shares of the company’s stock valued at $243,000 after purchasing an additional 23,689 shares during the last quarter. 88.23% of the stock is currently owned by hedge funds and other institutional investors.

About Sana Biotechnology

(Get Free Report)

Sana Biotechnology, Inc. is a clinical-stage biotechnology company founded in 2018 and headquartered in Seattle. It develops engineered cells intended to treat a range of diseases, including cancer, autoimmune disorders and conditions that may be addressed through cell replacement. The company’s research focuses on modifying cells to improve their therapeutic properties, including approaches designed to help transplanted cells evade immune rejection. Its programs include engineered immune-cell therapies and cell-replacement treatments, such as work involving insulin-producing cells for type 1 diabetes.

Read More

Receive News & Ratings for Sana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.